Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Eagle Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
EGRX
Nasdaq
2834
https://www.eagleus.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
- Apr 15th, 2024 11:00 am
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K
- Apr 12th, 2024 8:05 pm
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
- Jan 18th, 2024 11:50 am
Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City
- Dec 6th, 2023 9:05 pm
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q
- Nov 29th, 2023 12:35 pm
Eagle Pharmaceuticals Announces Management Change
- Nov 29th, 2023 12:30 pm
Down -33.75% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
- Nov 27th, 2023 2:35 pm
Down -26.73% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround
- Nov 10th, 2023 2:35 pm
Eagle Delays Third Quarter 2023 Results and Conference Call
- Nov 9th, 2023 12:30 pm
Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023
- Nov 8th, 2023 1:30 pm
Canopy Growth Corporation (CGC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Nov 2nd, 2023 2:00 pm
Eagle Pharmaceuticals Granted Patent for PEMFEXY®
- Oct 24th, 2023 12:40 pm
Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS
- Oct 23rd, 2023 10:50 am
Implied Volatility Surging for Eagle Pharmaceuticals (EGRX) Stock Options
- Oct 13th, 2023 12:36 pm
Shareholders in Eagle Pharmaceuticals (NASDAQ:EGRX) are in the red if they invested five years ago
- Oct 12th, 2023 11:23 am
Eagle Pharmaceuticals Awarded First Prize for Poster to Be Presented at the International Society for Anaesthetic Pharmacology 32nd Annual Meeting
- Oct 4th, 2023 10:50 am
Eagle Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023
- Sep 19th, 2023 8:05 pm
Eagle Pharmaceuticals to Present BYFAVO® (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) Conference
- Aug 30th, 2023 10:50 am
Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women
- Aug 29th, 2023 10:50 am
Eagle Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
- Aug 22nd, 2023 8:05 pm
Scroll